<SEC-DOCUMENT>0001077183-21-000098.txt : 20210407
<SEC-HEADER>0001077183-21-000098.hdr.sgml : 20210407
<ACCEPTANCE-DATETIME>20210407172056
ACCESSION NUMBER:		0001077183-21-000098
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210407
DATE AS OF CHANGE:		20210407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231608
		FILM NUMBER:		21813037

	BUSINESS ADDRESS:	
		STREET 1:		12701 COMMONWEALTH DRIVE
		STREET 2:		SUITE 9
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33913
		BUSINESS PHONE:		9419231949

	MAIL ADDRESS:	
		STREET 1:		12701 COMMONWEALTH DRIVE
		STREET 2:		SUITE 9
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33913

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>a424b7trapelo.htm
<DESCRIPTION>424B7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Filed Pursuant to Rule 424(b)(7)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registration No. 333-231608</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CALCULATION OF REGISTRATION FEE</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.370%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Title of Each Class</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">of Securities to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">be Registered</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amount</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">to be</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registered (1)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proposed</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Maximum</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Offering</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Price per share (2)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proposed</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Maximum</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Aggregate</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Offering Price (2)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amount of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registration</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fee (3)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common Stock, par value $0.001 per share</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">597,712</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$49.375</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$29,512,030</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$3,220</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement also registers such additional shares of common stock as may become issuable to prevent dilution as a result of stock splits, stock dividends or similar transactions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) Estimated in accordance with Rule 457(c) under the Securities Act solely for purposes of calculating the registration fee on the basis of the average of the high and low prices of the registrant&#8217;s common stock as reported on the Nasdaq Stock Market on April 5, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3) Calculated and being paid in accordance with Rule 456(b) and Rule 457(r) under the Securities Act. This &#8220;Calculation of Registration Fee&#8221; table shall be deemed to update the &#8220;Calculation of Registration Fee&#8221; table in the registrant&#8217;s Registration Statement on Form S-3ASR (File No. 333-231608).</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PROSPECTUS SUPPLEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(To prospectus dated May 20, 2019)</font></div><div><font><br></font></div><div style="text-align:center"><img alt="neologo1a.jpg" src="neologo1a.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:395px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">NeoGenomics, Inc.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">597,712 Shares of Common Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">_____________________________________________________________________________</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This prospectus supplement relates to the resale of up to 597,712 shares of our common stock, par value $0.001 per share, from time to time in one or more offerings by the selling stockholders identified in this prospectus supplement. We will not receive any proceeds from the resale of any of the shares being registered hereby. </font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The shares being registered hereby were issued to the selling stockholders in connection with our acquisition of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intervention Insights, Inc. d&#47;b&#47;a Trapelo Health</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;Trapelo&#8221;), pursuant to an Agreement and Plan of Merger dated as of March 23, 2021 entered into between Trapelo and our wholly owned subsidiary (the &#34;Merger Agreement&#34;).</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selling stockholders (which term as used herein includes their respective pledgees, donees, assignees, transferees, distributees or other successors-in-interest) may sell all or part of their shares registered hereby in public transactions or in privately negotiated transactions at market prices prevailing at the time of sale or at negotiated prices. The timing and amount of any sale are within the sole discretion of the selling stockholders. We provide more information about how the selling stockholders may sell, transfer or otherwise dispose of their shares of common stock in the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plan of Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; section of this prospectus supplement.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;NEO.&#8221; On April 6, 2021, the last reported sale price of our common stock on the Nasdaq Capital Market was $48.81.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">____________________________________________________________________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">_________</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investing in our securities involves risks. You should review carefully the risks and uncertainties described under the heading &#34;Risk Factors&#34; on page S-7 of this prospectus supplement.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">_____________________________________________________________________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">_____________________________________________________________________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The date of this prospectus supplement is April 7, 2021. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_39"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%">Prospectus Supplement</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:85.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.763%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_59" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">ABOUT THIS PROSPECTUS SUPPLEMENT</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_59" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_59" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ORWARD-LOOKI</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NG STATEMENTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-2</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">SUMMARY</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">S</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">-</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_80" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">THE OFFERING</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_80" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">S</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_80" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">-5</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_86" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_86" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-6</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_92" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_92" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_92" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">8</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_98" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">S</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_98" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ELLING STOCKHOLDERS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_98" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-</a><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_98" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">8</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_104" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_104" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-9</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_110" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_110" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-11</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_116" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_116" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-11</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_122" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_122" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-12</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_129" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">INCORPORATION BY REFERENCE</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_129" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">S-12</a></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%">Prospectus</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:93.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.225%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_144" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_144" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">ii</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_153" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">PROSPECTUS SUMMARY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_153" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_159" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_159" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_165" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_165" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_171" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_171" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">DESCRIPTION OF COMMON STOCK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">INCORPORATION BY REFERENCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline"><a href="#i7baf8a6c05b34ba0ab39b8b6b93d69d5_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">8</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_59"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ABOUT THIS PROSPECTUS SUPPLEMENT</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 (File No. 333-231608) that we filed with the Securities and Exchange Commission, or SEC, and that became automatically effective on May 20, 2019. This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds, updates and changes information contained in the accompanying prospectus and the documents incorporated herein by reference. The second part is the prospectus, which gives more general information, some of which may not apply to this offering of common stock.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the information contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus or any document incorporated herein by reference, you should rely on the information in this prospectus supplement. Before investing in our common stock, you should read this prospectus supplement and the accompanying prospectus, as well as the additional information incorporated by reference herein described under &#8220;Incorporation by Reference.&#8221; </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not authorized anyone to provide you with any information or to make any representation, other than those contained or incorporated by reference in this prospectus supplement and the accompanying prospectus or in any free writing prospectus we have prepared and to which we have referred you. We take no responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the underwriters are making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise stated, information in this prospectus supplement assumes no exercise of the underwriters&#8217; option to purchase additional shares.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRADEMARKS</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The &#8220;NeoGenomics&#8221;,&#8220;Genoptix&#8221; and &#8220;Clarient&#8221; names and logos have been trademarked with the United States Patent and Trademark Office. We also have trademarked or have applications pending for the brand names CHART, COMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOACTT, NEOARRAY, NEOCOMPLETE, NEOFISH, NeoLab, NEOGENOMICS LABORATORIES,  NeoLink, NeoLIQUID, NEONET, NEOREACH, NeoSCORE, NEOSEQ, NeoSITE, NEOSMART, NeoTYPE, NeoUniversity, NEOVUE, and PATHSITE. We also have trademarked or have pending trademarks for the marketing slogans &#8220;TAKING CANCER PERSONALLY&#8221;, &#8220;UNIVERSAL FUSION EXPRESSION&#8221;, &#8220;Unifying Cancer Care&#8221;, &#8220;UNIFYING, &#8220;NEOGENOMICS EUROPE&#8221;, and &#8220;WHERE PASSION MEETS PURPOSE&#8221;.  Any other trademarks, registered marks and trade names appearing in this prospectus or the documents incorporated by reference herein are the property of their respective holders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information included or incorporated by reference in this prospectus supplement, the accompanying prospectus and the documents incorporated herein by reference contain forward-looking statements &#8220;forward-looking statements&#8221; and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &#8220;Securities Act&#8221;, and Section 21E of the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning this offering, our strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth under &#8220;Risk Factors&#8221; and in our other filings with the SEC.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements include, but are not limited to, statements about&#58;</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to respond to rapid scientific change&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risk of liability in conducting clinical trials and the sufficiency of our insurance to cover such claims&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to implement our business strategy&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The anticipated impact to our business operations, customer demand and supply chain due to the recent global pandemic of a novel strain of the coronavirus (&#8220;COVID-19&#8221;)&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The expected reimbursement levels from governmental payers and private insurers and proposed changes to those levels&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The application, to our business and the services we provide, of existing laws, rules and regulations, including without limitation, Medicare laws, anti-kickback laws, Health Insurance Portability and Accountability Act of 1996 regulations, state medical privacy laws, international privacy laws, federal and state false claims laws and corporate practice of medicine laws&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Regulatory developments in the United States including downward pressure on health care reimbursement&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to maintain our license under the Clinical Laboratory Improvement Amendments of 1988, or CLIA&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Food and Drug Administration or FDA, regulation of Laboratory Developed Tests&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to timely or accurately bill for our services&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to expand our operations and increase our market share&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to expand our service offerings by adding new testing capabilities&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to meet our future capital requirements&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to manage our indebtedness&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to manage the quality of our investment portfolio&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to protect our intellectual property from infringement&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to integrate future acquisitions and costs related to such acquisitions&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The effects of seasonality on our business&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to maintain service levels and compete with other diagnostic laboratories&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to hire and retain sufficient managerial, sales, clinical and other personnel to meet our needs&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our handling, storage and disposal of biological and hazardous materials&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The accuracy of our estimates regarding reimbursement, expenses, future revenues and capital requirements&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to manage expenses and risks associated with international operations, including anti-corruption and trade sanction laws and other regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Other factors discussed under the caption &#8220;Risk Factors&#8221; in this prospectus and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which are incorporated by reference in this prospectus.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date made. You should read this prospectus supplement, including any documents incorporated herein by reference, and the accompanying prospectus completely and with the understanding that our actual future results may be materially different from what we expect.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_74"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This summary highlights selected information contained elsewhere, or incorporated by reference, in this prospectus supplement. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should carefully read this prospectus and the documents incorporated by reference herein, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained herein, and under a similar heading in other documents that are incorporated by reference into this prospectus. You also should carefully read the information incorporated by reference into this prospectus, including our financial statements and the exhibits to the registration statement of which this prospectus is a part. Unless the context otherwise requires, NeoGenomics, Inc. is referred to herein, collectively with all of its subsidiaries, as the &#8220;Company,&#8221; &#8220;NeoGenomics,&#8221; or &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our.&#8221;</font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate a network of cancer-focused testing laboratories in the United States as well as laboratories in Switzerland and Singapore. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to be the world&#8217;s leading cancer testing and information company by delivering uncompromising quality, exceptional service and innovative solutions.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Headquartered in Fort Myers, FL, NeoGenomics operates laboratories in Aliso Viejo, Carlsbad and San Diego, California&#59; Tampa and Fort Myers, Florida&#59; Houston, Texas&#59; Nashville, Tennessee&#59; Atlanta, Georgia&#59; Rolle, Switzerland&#59; and Singapore. NeoGenomics serves the needs of two primary types of customers&#58; Clinical and Pharma. Our Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Our Pharma customers include pharmaceutical companies to whom we provide testing and other services to support their studies and clinical trials.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal executive offices are located at 12701 Commonwealth Drive, Suite 9, Fort Myers, Florida 33913. Our telephone number is (239) 768-0600. Our principal website can be accessed at www.neogenomics.com. The information on or accessible through any of our websites is deemed not to be incorporated in this prospectus supplement or to be part of this prospectus supplement.</font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acquisition of Trapelo</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 7, 2021, we acquired all of the equity of Trapelo pursuant to the Merger Agreement. Pursuant to the terms of the Merger Agreement, at the closing, we paid cash consideration of approximately $30.9 million and issued 597,712 shares of the Company&#8217;s common stock to certain of Trapelo&#8217;s equityholders that are accredited investors. Under the terms of the Merger Agreement, we agreed to register for resale such shares of our common stock. The 597,712 shares of our common stock we issued pursuant to the Merger Agreement are the shares being registered for resale hereby.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-4</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_80"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE OFFERING</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common Stock Offered by Selling Stockholders&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">597,712 shares</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Use of Proceeds&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will not receive any proceeds from the sale of our shares of common stock by the selling stockholders.</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Factors&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; and other information contained herein or otherwise incorporated by reference herein before deciding to invest in shares of our common stock.</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nasdaq Capital Market Symbol&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;NEO.&#8221;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-5</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_86"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISK FACTORS </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in our securities involves risks. You should carefully consider the risks described herein and those described under &#8220;Risk Factors&#8221; in Part I, Item IA of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as all other information contained or incorporated by reference into this prospectus supplement, before making an investment decision. Our business, results of operations, cash flows and financial condition could be materially adversely affected by any of these risks. The market or trading price of our securities could decline due to any of these risks. In addition, please read &#8220;Special Note About Forward-Looking Statements&#8221; in this prospectus supplement, where we describe additional uncertainties associated with our business and the forward-looking statements included or incorporated by reference in this prospectus. Please note that additional risks not presently known to us or that we currently deem immaterial may also impair our business and operations.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the COVID-19 Pandemic</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic is highly dynamic in the United States and throughout the world and has adversely and is continuing to adversely affect our business, results of operations and financial condition.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to risks related to the public health crises such as the global pandemic associated with COVID-19. Economic and health conditions in the United States and across most of the globe continue to change rapidly. Due to the COVID-19 pandemic, the Company has experienced significant volatility, including periods of material decline compared to prior year periods, in testing volumes in the Company&#8217;s base business (which excludes COVID-19 molecular and antibody testing). Demand may fluctuate depending on the duration and severity of the COVID-19 pandemic, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and&#47;or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business disruption, reduced revenues and number of tests, any of which could materially affect our business, financial condition, and results of operations.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Starting in mid-March 2020, the governor of California, where several of our laboratories are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel and business operations for an indefinite period of time, subject to certain exceptions for necessary activities, which was followed by similar orders in other states in which we operate, including in Florida, where our headquarters is located. Various orders have been implemented and subsequently relaxed however, disruptions continue and have carried into 2021. Such orders or restrictions, have resulted in our administrative headquarters closing, work stoppages, slowdowns and delays, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions include restrictions on our personnel and personnel of partners to travel and access customers&#59; delays in approvals by regulatory bodies&#59; delays in product development efforts&#59; and additional government requirements or other incremental mitigation efforts that may further impact our testing capacity.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic is affecting the Company&#8217;s customers, suppliers, vendors, and other business partners, but the Company is not able to assess the full extent of the current impact nor predict the ultimate consequences that may result. At this time, we have not experienced interruptions in our operations due to supplier delays. We have established a COVID-19 procurement team to partner with our suppliers to reduce the risk of disruption. Distribution channels have not been disrupted as incoming and outgoing tests are delivered via major carriers.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the potential economic impact brought by and the duration of COVID-19 may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. The Company is continuously monitoring its own operations and intends to take appropriate actions to mitigate the risks arising from the COVID-19 pandemic to the best of its abilities, but there can be no assurances that the Company will be successful in doing so. To the extent the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is able to obtain information about and maintain communications with its customers, suppliers, vendors, and other business partners, the Company will seek to minimize disruptions to its supply chain. The ultimate extent of the effects of the COVID-19 pandemic on the Company, including revenue generated from COVID-19 PCR testing, is highly uncertain and will depend on future developments which cannot be predicted.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section and the Risk Factors contained in and incorporated by reference herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Ownership of Our Common Stock</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The price of our common stock has, and is likely to continue to, fluctuate significantly. </font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The price of our common stock has been, and is likely to continue to be, volatile, which means that it could decline substantially within a short period of time. The price of our common stock could fluctuate significantly for many reasons including the following&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">future announcements concerning us or our competitors&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">regulatory developments and enforcement actions bearing on advertising, marketing or sales&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">reports and recommendations of analysts and whether or not we meet the milestones and metrics set forth in such reports&#59; gaining or losing large customers or managed care plans&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">introduction of new products or services and related insurance coverage&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the impact of the COVID-19 pandemic on our business or prospects&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">acquisition or loss of significant manufacturers, distributors or suppliers or an inability to obtain sufficient quantities of materials needed to provide our services&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">quarterly variations in operating results, including fluctuations in the mix of products and services sold, which could result in fluctuations in gross profit, or fluctuations in operating expenses, either of which could result in fluctuations in income from operations&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">business acquisitions or divestitures&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">changes in the regulation of Laboratory Developed Tests&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">fluctuations in the economy, political events or general market conditions&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">changes in governmental or third-party reimbursement practices and rates.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, stock markets in general and the market for shares of health care stocks in particular, have experienced extreme price and volume fluctuations in recent years, and are experiencing exceptional volatility as a result of the effects of the COVID-19 pandemic. Moreover, these fluctuations frequently have been unrelated to the operating performance of the affected companies. These broad market fluctuations may adversely affect the market price of our common stock. The market price of our common stock could decline below its current price and the market price of our shares may fluctuate significantly in the future. These fluctuations may be unrelated to our performance, and could lead to securities class action litigation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-7</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_92"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">USE OF PROCEEDS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selling stockholders will make offers and sales pursuant to this prospectus supplement and the accompanying prospectus. We will not receive any of the proceeds of such offerings. The selling stockholders will pay any underwriting discounts and commissions and expenses they incur for brokerage, accounting, tax or legal services, or any other expenses they incur in disposing of their shares. We will incur certain expenses in connection with the registration with the SEC of the shares of our common stock to be sold by the selling stockholders. </font></div><div style="text-indent:18pt"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_98"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SELLING STOCKHOLDERS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This prospectus supplement relates to the resale of up to 597,712 shares of our common stock that may be sold by the selling stockholders set forth herein. The shares being registered hereby were issued to former equityholders of Trapelo in connection with our acquisition of Trapelo pursuant to the Merger Agreement. Pursuant to the Merger Agreement, we agreed to register for resale the shares of our common stock that we issued pursuant to the Merger Agreement. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary&#8212;Recent Developments&#8212;Acquisition of Trapelo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information. When we refer to &#8220;resales&#8221;, &#8220;sales&#8221; or &#8220;selling&#8221; by the selling stockholders in this prospectus, we mean any sale, transfer or other disposition in accordance with the plan of distribution described herein.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth certain information known to us, based upon written representations from the selling stockholders, with respect to the beneficial ownership of our shares of common stock held by the selling stockholders as of April 7, 2021, the closing date of our acquisition of Trapelo. Because the selling stockholders may sell, transfer or otherwise dispose of all, some or none of the shares of our common stock covered by this prospectus supplement, we cannot determine the number of such shares that will be sold, transferred or otherwise disposed of by the selling stockholders, or the amount or percentage of shares of our common stock that will be held by the selling stockholders upon termination of any particular offering. See the section of this prospectus supplement captioned &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plan of Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information. For purposes of the table below, we assume that the selling stockholders will sell all their shares of common stock covered by this prospectus supplement.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to our common stock. Beneficial ownership information presented in this table is not necessarily indicative of beneficial ownership for any other purpose.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When we refer to the &#8220;selling stockholders&#8221; in this prospectus supplement, we include their respective pledgees, donees, assignees, transferees, distributees or other successors-in-interest.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise set forth in the footnotes to the table below, based on the information furnished to us by the selling stockholders, no selling stockholder had any position, office or other material relationship within the past three years with us or with any of our predecessors or affiliates. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the table below, the percentage of shares beneficially owned is based on 117,048,193 shares of our common stock outstanding on April 1, 2021.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of Common Stock Beneficially Owned Prior to this Offering</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of Common Stock Being Registered Hereby</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of Common Stock Beneficially Owned after Completion of this Offering</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling Stockholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan Growth Capital Partners, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,257</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,257</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Entities affiliated with Chrysalis Ventures (1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,623</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,623</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hopen Life Science Fund II, L.P.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,846</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,846</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hopen C, LLC </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,858</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,858</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan Accelerator Fund I</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,260</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,260</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charter Intervention Fund, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,809</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,809</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legacy Life Sciences, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,101</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,101</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MAS Health Ventures, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">920</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">920</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PM3, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HC Capital Partners, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charter Intervention Fund 2.0, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,199</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,199</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ann Arbor SPARK</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Western Michigan University</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JKMCurren, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TWB Investments, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">City of Hope</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,666</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,666</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Henson Enterprises, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,543</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,543</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other selling stockholders (2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,538</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,538</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All selling stockholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597,712</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597,712</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Less than 1%</font></div><div><font><br></font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1) Consists of (i) 148,037 shares of common stock held of record by Chrysalis Ventures III, L.P., (ii) 21,656 shares of common stock held of record by Chrysalis Ventures (Ohio) III, L.P. and (iii) 23,930 shares of common stock held of record by Chrysalis Ventures (Healthcare) III, L.P. </font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Consists of 12 selling stockholders not listed above who, as a group, beneficially own less than 1% of our outstanding common stock prior to this offering.</font></div><div><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_104"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PLAN OF DISTRIBUTION</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The shares of our common stock covered by this prospectus supplement may be offered and sold from time to time by the selling stockholders. The term &#8220;selling stockholders&#8221; includes pledgees, donees, assignees, transferees, distributees or other successors-in-interest selling shares received after the date of this prospectus supplement from a selling stockholder as a gift, pledge, partnership distribution or other non-sale related transfer. A selling stockholder may decide to sell all or a portion of the shares offered by it pursuant to this prospectus supplement or may decide not to sell any shares under this prospectus supplement. The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges in any market or trading facility on which the shares are traded, or in the over-the-counter market or otherwise, at fixed prices, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling stockholders may sell their shares by one or more of, or a combination of, the following methods&#58;</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">an exchange distribution in accordance with the rules of the applicable exchange&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">privately negotiated transactions&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">short sales effected after the date the registration statement of which this prospectus forms a part is declared effective by the SEC&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">a combination of any such methods of sale&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">any other method permitted by applicable law.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus, amending the list of selling stockholders to include the pledgee, transferee or other successors-in-interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the pre-funded warrants or Warrants by payment of cash, however, we will receive the exercise price of the pre-funded warrants or Warrants.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have agreed with the selling stockholders to use commercially reasonable efforts to cause the registration statement of which this prospectus forms a part to remain continuously effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act. </font></div><div><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_110"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LEGAL MATTERS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The validity of the shares of common stock being offered by this prospectus supplement will be passed upon for us by Snell &#38; Wilmer L.L.P., Reno, Nevada. </font></div><div style="text-indent:18pt"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_116"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXPERTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements as of December 31, 2020, and for each of the years in the two-year period ended December 31, 2020 incorporated in this Prospectus by reference from NeoGenomics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, and the effectiveness of NeoGenomics, Inc. and subsidiaries&#8217; internal control over financial reporting have been audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements of NeoGenomics, Inc. as of December 31, 2018, and for the year ended December 31, 2018 incorporated in this prospectus by reference to NeoGenomics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 have been incorporated in reliance on the report of Crowe LLP, independent registered public accounting firm, given on authority of said firm as experts in auditing and accounting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-11</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_122"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We file reports and other information with the SEC as required by the Exchange Act. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http&#58;&#47;&#47;www.sec.gov.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC. The registration statement contains more information than this prospectus supplement and the accompanying prospectus regarding us and the securities offered by this prospectus supplement, including exhibits and schedules. You can obtain a copy of the registration statement from the SEC at any address listed above or from the SEC&#8217;s web site.</font></div><div style="text-indent:18pt"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_129"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INCORPORATION BY REFERENCE</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the following documents and all documents we file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) pursuant to the Exchange Act on or after the date of this prospectus supplement and prior to the termination of the offering under this prospectus (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our Proxy Statement on Schedule 14A filed on April 14, 2020 (excluding those portions that are not incorporated by reference into our Annual Report on Form 10-K)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our Current Report on Form 8-K filed on March 1, 2021 (other than any exhibits furnished thereon)&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the description of our Common Stock contained in the registration statement on Form 8-A (Registration No. 000-54384), filed with the SEC under Section 12(g) of the Exchange Act on May 2, 2011, as updated by the description of our Common Stock set forth in the Prospectus Supplement to our Registration Statement No. 333-186067 filed with the SEC pursuant to Rule 424(b)(5) on February 28, 2013, and any amendment or report filed with the SEC for the purpose of updating the description.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any statement contained herein or in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this prospectus supplement, except as so modified or superseded.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby undertake to provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus supplement is delivered, upon written or oral request of any such person, a copy of any and all of the information that has been incorporated by reference in this prospectus supplement, other than exhibits to such documents, unless such exhibits have been specifically incorporated by reference thereto. Requests for such copies should be directed to our Investor Relations department, at the following address&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NeoGenomics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12701 Commonwealth Drive, Suite 9</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fort Myers, Florida 33913</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(239) 768-0600</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-12</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_135"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><img alt="image_21a.jpg" src="image_21a.jpg" style="height:113px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">NeoGenomics, Inc.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Common Stock</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________________________________&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, offer to sell shares of common stock, $0.001 par value (&#8220;Common Stock&#8221;) in one or more offerings. This prospectus describes some of the general terms that may apply to such offerings. Each time we offer and sell Common Stock, we will provide the specific terms in a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the shares of Common Stock being offered. The supplement may also add, update or change information contained in this prospectus with respect to any such offering. You should read this prospectus and the applicable prospectus supplement carefully before you invest in any shares of our Common Stock.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We may offer and sell shares of Common Stock to or through one or more underwriters, dealers and agents or directly to purchasers, or through a combination of these methods, on a continuous or delayed basis. If any underwriters, dealers or agents are involved in the sale of shares of Common Stock, the applicable prospectus supplement will set forth the applicable purchase price, fee, commissions or discounts between or among them. Our net proceeds from the sale of Common Stock will be the public offering price less the applicable discount, in the case of an offering made through an underwriter, or the purchase price less the applicable commission, in the case of an offering through an agent, and, in each case, less other expenses payable by us in connection with the issuance and distribution of such shares of Common Stock. See the sections of this prospectus entitled &#8220;About this Prospectus&#8221; and &#8220;Plan of Distribution&#8221; for more information. No shares of Common Stock may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such shares of Common Stock.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We may amend or supplement information contained in this prospectus from time to time. You should carefully read this prospectus and any amendments or supplements before you invest in shares of our Common Stock.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock is listed on the NASDAQ Capital Market under the symbol &#8220;NEO.&#8221; On May 17, 2019, the last reported sale price of our Common Stock on the NASDAQ Capital Market was $22.99 per share.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE &#8220;RISK&#160;FACTORS&#8221; ON PAGE 2 OF THIS PROSPECTUS, AS WELL AS RISK FACTORS DESCRIBED UNDER THE HEADING &#8220;RISK&#160;FACTORS&#8221; IN OUR MOST RECENT ANNUAL REPORT ON FORM 10-K, AS AMENDED, AND EACH SUBSEQUENT QUARTERLY REPORT ON FORM 10-Q (WHICH DOCUMENTS ARE INCORPORATED BY REFERENCE HEREIN), BEFORE YOU INVEST IN SHARES OF OUR COMMON STOCK.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The date of this prospectus is May 20, 2019.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-14</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_222"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:93.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.225%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">ABOUT THIS PROSPECTUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">ii</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">PROSPECTUS SUMMARY</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">RISK FACTORS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">FORWARD-LOOKING STATEMENTS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">USE OF PROCEEDS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">DESCRIPTION OF COMMON STOCK</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">PLAN OF DISTRIBUTION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">LEGAL MATTERS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">EXPERTS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">INCORPORATION BY REFERENCE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">8</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_144"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) as a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities we may offer. Each time we offer the securities described in this prospectus, we will provide a prospectus supplement to this prospectus that will contain specific information about the terms of that offering. Such prospectus supplement may add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you should rely on the prospectus supplement. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement, together with the additional information described under the heading &#8220;Incorporation by Reference.&#8221; We may also prepare free writing prospectuses that describe particular securities. Any free writing prospectus should also be read in connection with this prospectus and with any prospectus supplement referred to therein. For purposes of this prospectus, any reference to an applicable prospectus supplement may also refer to a free writing prospectus, unless the context otherwise requires.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus does not contain all the information provided in the registration statement filed with the SEC. You should carefully read both this prospectus and any prospectus supplement together with the additional information described below under &#8220;Where You Can Find More Information&#8221; before you make an investment decision.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized any other person to provide you with information that is different from that contained in or incorporated by reference herein, in any related prospectus supplement or in any related free writing prospectus. We do not take any responsibility for, and can provide no assurance as to the reliability of, any other information, that others may give you.  You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate as of the date on its respective cover, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_153"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights selected information contained elsewhere, or incorporated by reference, in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should carefully read the entire prospectus, any accompanying prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained herein and in any accompanying prospectus supplement and any related free writing prospectus, and under a similar heading in other documents that are incorporated by reference into this prospectus. You also should carefully read the information incorporated by reference into this prospectus, including our financial statements and the exhibits to the registration statement of which this prospectus is a part. Unless the context otherwise requires, NeoGenomics, Inc. is referred to herein, collectively with all of its subsidiaries, as the &#8220;Company&#8221;, &#8220;NeoGenomics&#8221;, or &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a network of cancer-focused genetic testing laboratories in the United States, Europe and Asia.&#160;We believe the Company provides one of the most comprehensive oncology-focused testing menus in the industry for physicians to help diagnose and treat cancer. The Company&#8217;s Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to become the world&#8217;s leading cancer testing and information company by delivering uncompromising quality, exceptional service and innovative solutions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Fort Myers, FL, NeoGenomics operates laboratories in Aliso Viejo, Carlsbad and Fresno, California&#59; Tampa and Fort Myers, Florida&#59; Houston, Texas&#59; Nashville, Tennessee&#59; Atlanta, Georgia&#59; Rolle, Switzerland&#59; and Singapore.&#160;&#160;NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Us</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 12701 Commonwealth Drive, Suite 9, Fort Myers, Florida 33913. Our telephone number is (239) 768-0600.&#160;Our principal website can be accessed at www.neogenomics.com.&#160;The information on or accessible through, any of our websites is deemed not to be incorporated in this prospectus or to be part of this prospectus.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_159"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K, as amended, and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the risk factors and other information contained in the applicable prospectus supplement before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_165"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information in this prospectus, including information in documents incorporated by reference in this prospectus contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, relating to NeoGenomics, Inc., a Nevada corporation and its subsidiaries, NeoGenomics Laboratories, Inc., a Florida corporation (&#8220;NeoGenomics Laboratories&#8221;), NeoGenomics Bioinformatics Inc., a Florida corporation, Genesis Acquisition Holdings Corp., a Delaware corporation and its wholly owned subsidiaries, Genoptix, Inc., Minuet Diagnostics, Inc. and Cynogen, Inc. (together &#8220;Genoptix Medical Laboratories&#8221;), Clarient, Inc., a Delaware corporation and its wholly owned subsidiary, Clarient Diagnostic Services, Inc. (together &#8220;Clarient&#8221;) (collectively referred to as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;NeoGenomics&#8221;, or the &#8220;Company&#8221;), which are subject to the &#8220;safe harbor&#8221; created by those sections.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, &#8220;plans&#8221;, &#8220;projects&#8221;, &#8220;will&#8221;, &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth under &#8220;Risk Factors&#8221; herein and in Part I, Item 1A, &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K filed with the SEC on February 26, 2019, as amended by a 10-K&#47;A filed with the SEC on May 8, 2019 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_171"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_178"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary description of our common stock is based on the provisions of our articles of incorporation, as amended (&#8220;Articles of Incorporation&#8221;), as well as our amended and restated bylaws, as amended (&#8220;Bylaws&#8221;), and the applicable provisions of Chapter 78 of the Nevada Revised Statutes. This information is qualified entirely by reference to the applicable provisions of our Articles of Incorporation, Bylaws and Chapter 78 of the Nevada Revised Statutes. For information on how to obtain copies of our Articles of Incorporation and Bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find More Information.&#8221; As of the date of this prospectus, our authorized capital stock consists of 250,000,000 shares of Common Stock and 50,000,000 shares of preferred stock, $0.001 par value. No shares of preferred stock are currently outstanding.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 17, 2019, we had 95,469,780 shares of Common Stock outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The holders of Common Stock are entitled to one vote per share for the election of directors and with respect to all other matters submitted to a vote of stockholders. Shares of our Common Stock do not have cumulative voting rights, which means that the holders of more than 50% of such shares voting for the election of directors can elect 100% of the directors if they choose to do so.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The holders of Common Stock are entitled to share equally in dividends, if, as and when declared by our Board of Directors (the &#8220;Board&#8221;), out of funds legally available therefore, subject to the priorities given to any class of preferred stock which may be issued.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Upon&#160;liquidation, dissolution or winding-up of NeoGenomics, our assets, after the payment of debts and liabilities and any liquidation preferences of, and unpaid dividends on, any class of preferred stock then outstanding, will be distributed pro-rata to the holders of our Common Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Rights and Preferences.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our Common Stock do not have preemptive or conversion rights to subscribe for any of our securities and have no right to require us to redeem or purchase their shares. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fully Paid and Non-assessable.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding shares of our Common Stock are fully paid and&#160;non-assessable.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_184"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods or through underwriters or dealers, through agents and&#47;or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at a fixed price or prices, which may be changed&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at market prices prevailing at the time of sale&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at prices related to such prevailing market prices&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at negotiated prices.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and&#47;or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Common Stock will be listed on the NASDAQ Capital Market, but any other securities may or may not be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In compliance with the guidelines of the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;), the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate proceeds of the offering. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </font></div><div style="text-align:justify"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_190"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the shares of Common Stock offered by this prospectus has been passed upon for us by Snell &#38; Wilmer L.L.P., Reno, Nevada. </font></div><div><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_196"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The consolidated financial statements of NeoGenomics, Inc. as of December 31, 2018, and for each of the years in the three-year period ended December 31, 2018 incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2018, as amended, have been incorporated in reliance on the report of Crowe LLP, independent registered public accounting firm, given on authority of said firm as experts in auditing and accounting.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The financial statements of Genesis Acquisition Holdings Corp. and subsidiaries (the &#34;Successor Company&#8221;) as of December 31, 2017 and for the period March 1, 2017 to December 31, 2017, and Genoptix, Inc. and subsidiaries (the &#8220;Predecessor Company&#34;) for the period January 1, 2017 to February 28, 2017 and as of and for the year ended December 31, 2016 incorporated in this prospectus by reference, have been audited by Deloitte &#38; Touche LLP, independent auditors, as stated in their report, which is incorporated herein by reference (which report expresses an unqualified opinion and contains emphasis-of-matters paragraphs that describes (1) that the financial statements for the Successor Company and Predecessor Company do not purport to be comparable to other periods as a result of the business combination on March 1, 2017 and (2) that the separate accounts and records maintained by the Predecessor Company have been prepared by Novartis Finance Corporation (&#8220;Novartis&#8221;) and include certain allocations of costs from Novartis that may not necessarily be indicative of the conditions that would have existed or the results of operations if the Predecessor Company had been operated as a separate entity apart from Novartis). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such financial statements have been incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_202"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file reports and other information with the SEC as required by the Exchange Act. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http&#58;&#47;&#47;www.sec.gov.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement that we filed with the SEC. The registration statement contains more information than this prospectus regarding us and the securities, including exhibits and schedules. You can obtain a copy of the registration statement from the SEC at any of the sources listed above.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i7baf8a6c05b34ba0ab39b8b6b93d69d5_208"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the following documents and all documents we file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) pursuant to the Exchange Act on or after the date of this prospectus and prior to the termination of the offering under this prospectus or any prospectus supplement (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules)&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on February 26, 2019, as amended by a 10-K&#47;A filed with the SEC on May 8, 2019&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Proxy Statement on Schedule 14A filed on April 22, 2019 (excluding those portions that are not incorporated by reference into our Annual Report on Form 10-K)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Quarterly Report on Form 10-Q for the period ending March 31, 2019, filed with the SEC on May 8, 2019&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Current Reports on Form 8-K filed with the SEC on December 10, 2018, March 5, 2019 and May 20, 2019&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the description of our Common Stock contained in the registration statement on Form&#160;8-A (Registration No.&#160;000-54384), filed with the SEC under Section&#160;12(g)&#160;of the Exchange Act on May 2, 2011, as updated by the description of our Common Stock set forth in the Prospectus Supplement to our Registration Statement No. 333-186067 filed with the SEC pursuant to Rule 424(b)(5) on February 28, 2013.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statement contained herein or in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this prospectus, except as so modified or superseded.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby undertake to provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request of any such person, a copy of any and all of the information that has been incorporated by reference in this prospectus, other than exhibits to such documents, unless such exhibits have been specifically incorporated by reference thereto. Requests for such copies should be directed to our Investor Relations department, at the following address&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12701 Commonwealth Drive, Suite 9</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fort Myers, Florida 33913</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(239) 768-0600</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_21a.jpg" src="image_21a.jpg" style="height:203px;margin-bottom:5pt;vertical-align:text-bottom;width:446px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.512%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_21a.jpg
<TEXT>
begin 644 image_21a.jpg
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M^;0?. C:2$\KW(KUP1C2;B]\26I(NH,R"&+TS1DF+II>:PR=U@\MB<@^GM+
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M#6W7B$*Q@+4KV(0%K?EOS>YG4%CY*Y11TZNZ N4L7%W#E(8KM(-#36_D5_;
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MXE#% !<6K^Z'PI67X/FU=Z*A\:S\)K*(MW.!C]0J)D_QQ6EH\@>[/\=WQJ;
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M30^A<$4/:5<DP%?3R_C[V)F]'PJ6]<*Z?>IWH(W-G<J@S^DYL.%Y'YG I\)
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M<JFH[HV"99>C<MMT ];4UD-U_4#/T_6 3XF0]\V4!P6851^S@'DRG#$>6DH
MVI^8-W@\+0F#I^!/,_^F<R-!5H&.*8_7^^+?K@A\-!EK7B0C8+49Z\4WYF#_
M"0WO5MN/D;+%#A1)[[5<H03'N007V@@T4MC7VN8:5*%*)V_WP2.XZ->F]V
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M4]O7;M/[_RK^3C1G $^\M1I.+".YK3;.K??U['=_;!HF9#PO\ZY6.-\%!SI
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M!%JO^X>E8M"?'Y6U3(Y,3"$6D9]XPY>0 Q\'E_\.GCR#G]Q>!F<40XD)?(S
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M*'$RLUZHA#,D18-;K.G2"N.!;*EQ#$Y"VKSWA$:$7B2P)JKQ><X7>:GR4_I
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M]%Z%Z";CDFY6=7C=M14)W,F>@#><RJ3F;E">2\F:T,MT38H9*V6,7;O?:-,
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MII\CLS7KK,",;RW6<FVS/9<QC_:?.8>D7V7K3@.TJ"FPXTZ2:GP/>C^2%$*
MD1HXED*$*2OL,#1DDH+NX FX:>1$_,<OLM'_R3S\.N=]I*W9@,6?;,2K^=NQ
M=L,^N'8<@6_W<6P^= ;>O<>Q;N<1L!_IJ^X=6/K91F2_%\#32S["L-_GH<>O
M<_"7=TV'8_ X. :-E](?AW2>"84#!)Q&9XJR2/<LQT:O260^"I^?YE[/TDS0
M05-Q\XC)>,EENML(W3770UVY-("J)*[9-#DGOCD-EQ7M"'S<?E[!9/S*+TT;
M&P;=R32Z,&^PF5+]GT'FN[HI;7UMK>ZS)L G8=Q6^.A;0Q".M0Y?[#M&?*@
M "  241!5)J.N:Z>R&522W WAF1M5^9/E=C?H7-?&N C\&CCY'"B=MSK3N"+
M26MF!<N#6J+RX@_F<*NLY[20O8$@;6ZAMN1S%6S7UN*S8Z!&S3%;L+/"2K5T
MU=1YK.E[U?(C'[=:?J3?V\_L[^,YM_VM?;;GL._Y;(^%GU=!@QF%;(68#L?(
MV;AAZ/-XVUL4MD;CEP?,$;;Q+].("F<O7\%=4U[2OIZF&U5#,([%(^KI$F^7
M9'Z&?9>6CR1WL"2 5CIC:+2&& [B??-SQL&8$4JOA2D6YP8  \?K8_!$=+E]
M,O[DCFFX>=0T?&O,=/S%Z"GXTU%3T&7X9#B&3)0R"OD^+3IN"CMT"AQWL &[
MCHWR6,)0LKN)NC/EO8Q'X\8:*N#8R6>6M\+NI<5K:JY8Z/_\P!Q\:K9Q(ES4
MLB4:W=36VI,8K?8&U;P#RKSXY[/Q;]H<^#2+BOYU6D(J;-[T%N'&H>/A:%0X
M+,S*Q3EH$NZ:\9IA5.UGQZ[;E%:-!]PV[PUQ39HPQTFY6%5W$:LV_4 *UUFO
M%WIH_5Z.KR<6^D?B0L5>&:M:IB89N-W&&HL&G< 7FQ\T&4"RU0SR'2Z^B+^[
M=YJZWL=06)IL8VXS<U4MEJPPH,"@4- 87\>7,S060@J$+1?0C7__57E/L&"7
MGEFRL\8__S -)\Z7&9G"-41A6BL)$BJ;8JVKAI_1ZT0>XE]U/?#TT@_1A=F-
M0UDR8C(T@U9SJ(1!%8]P^G$N(LT' <2"B '(\/?RVOY6?]_DW)2CO'<",A\C
M^3P[]%Z4H AC"8*N&B4W\+?R73M.JS"%7]^^YOG"/P\_/U^;<XRA$L7Q$<P)
MWC-D'\2^3[V _6<OAN9(RBK4XT?9*ML<T>,LX;.&<Q)[W3?_W78"OK#46@![
MSIS#7XV:(-I8Q 5X^PQ\]Z$T%)>5&R(0B9A6VSXWK8RO%JD0U<2!3EW>AES/
M -EV* 1Z(0#,\G3'J@T_16V]Z21 M!3 :TWF6/.3T_SD=@)?<S22J34!<KJO
M^+?@DT)-RY88A8DUM$EANR[TZPOX&@NCK^=[$:S2F6>V@M^ YS!FZDJK>Z->
MZH.Y7KAD^6SE2WSK4!@(P)L%._%WWY^N^XT*^!$XYD@#]!M&A5G;P19Y7T^Z
M6WEN+?.0)4BP:]P/-P..8=/A&#0.OYV_%F4UVMRZ3DK8Z'!3RT[E?GSSTIP<
M:/QYFP,?+T ?IUS((%=Y=0U2GERB)GI$4W@.'(.>Q3L;C'N"N%</5O6U2W*+
M"$/^0S>8=6D V'!T.=+S$X,=6L+!C[&^#'=W?+X_3;*I),-8-$&.M7TG*?KY
M.X$O.FTX)UH'2NG'=DM,GR)OTBLQ?-)*([0(5EJCQ5VXFVC2$?DUFA!K"GS7
MIIPAVOB^SL=IO9/^W!6 !>=LB?@,YKRV3K"*]D,-URD--]'+%?QB\T^4=6W0
M;^^),Q@V886Z/D>88FY:-V%6D*W]4U?MUY'^I#FS76V) ^^1UJMZ4\0B'$LK
M<J[$1__Y_AEX;?TV0\%ZU-"E*7/"26$\SV!'.\O4=@(^:P&IY<:[_&GN^T;0
M1)I\S9CZ^?SWE""&.17XVIX0BL=*:-;$J"%0C;>V_0J9!=R**&3EA5ZGP)F?
MA!VGWI8Q<L'PAQ($EY=1%DF[3F G\,467*'T9^XCQCP%B<FR0/GD.7SK+G:)
M,!U.1&AR\4;BSY8>ZP0^:P%T]#,!QC':=.5A7(Q;48V8@3\;\CS6;K"A"75]
M2\:3=#&)7[:("T[".*)&H:J^'G/>=.,;HYF%R2W85/!SXU6"W8VCITLS@9!+
ML*6\]-7X'NDN^^>%N4?%^A,KF+%7;NK,C-MQ>&#FRSA6K*Y-!I=JI'S,&@[2
M=TF36#H _-H%^(C:9!!U*:IO?.7ZK9I48/R^PJCAVO2P:?B/QW)PN8I)MF+J
MF7-8$&T[8%'@8U)*3;"FY=R5/5C@&2&=64)@%P+ ;%\2%A8,1W&Y[=C"\3!F
MP'AAVXTMMB!O?)U.X(M-+U/C*T%<-K)6C=^4_V+NFVZ)-8@V+BXI[A*MX-4Z
MP=T)?*VCV]4)>0$8R4;D_%GP8T)(NB1P?.>^V2@Z83>\YHIE:SO*%2MT&Z^K
M9MZ+8J[?46$%;#UP$F,GO03'('8VF206CB:+T.5'"TAC?]>"/NUY3:4]K5S>
M8[ID:MXT>H8F,0[GKNG/X_\]DHV7PO8D5%Q@YJ;*=N9S4"6A*B%)M*TN06EF
MWL+D=#L#7ZUDU9$YBHZ=PE^-9?<,UN]%8/31LW'CL GX9)O9U5R84@5[;.'6
M\IL-G4<U?]'_%)>Q^<0JI.<GA^W"$ (] F&FMSM6;_H9JFK/"Z]3Z>/YY!QA
M! U=HS7CBO<WG< 7F]Y6L'&!:?:MNKE,,E--#08\M5 ["Q'X1!&SSQ%X-%Q1
MB_BZ$_C:4\C&.K<H+Y*A:K(?[YQADHSFRG8Y/7XY#^=**V3M4KAJ*Z_6*-5<
M^+HMCWB*>+*PNKI5ZS>CVV-.S6*GI2,N/_+%U?!5:WBQ(W]#ZY:N39.!>L=L
M:1;QS;MF8\*R3U!2:G(WZ%T3Y9,)@2Q18'<=E<5J1- AK6LU]KJ.5TXV_7Z[
M )_V?./%3$V>48N2GWS!Q/F::M7BGQ\P'K_*4U>B=4>V#P%4($IH50"V"F]M
M>1P9!5VCNCG3W%WQZ;Y9"GH$.A.'Y#VVSQB;3E;#ZUBE0)'[Z@O8QWWM6I9Q
M>5FO@P@[>:\ *)HE@(V'3N#FT=/$Y1E+L+;LLTC -PEK"G:%^"9.)8D_W''\
M(O['W6SJ;H5Y1PJUK\BUQK ,@);'#%,"8,8MS3*8.C\.8Z:^)%F9I.G5 A]#
M),PZI->(PIRQ*OO'W0LRWEB'?WHP3>H*'<.X98_-?OR*T#.B8A=M[ 3U65H:
M,6 "_N+.Z?B9\PWI=VII0NM.A*:QEM5EK!X9FMXDGW@)Q=IK?YG:+L#74$ +
MLLC]/[_\8S@&L(;*&4IU%3< 4\IG24>)[_TD$^<JU'^NKHCV(D((E,^6;<$\
MSS!D^Q*0YT\&&U.S3=D\+W=DZ(WL0"*R\WMC3['&($73,Q.HM27-@51;?JX:
M$K@O%AOQ&LZ:^N(GP28!+1/284Q,__R@\7C^)>W5*4PH23_68FK+\5^#<\EB
M:G@OT@S=%&A-7;U.$Q3H)HMKP8?14'YG-/LQ-E-T#KH,&X^W6PE\5I;N/'$!
MW[Q'!8LF<#2^;N?[8.J\  Q!AG.A.RIH[3"3*Y[#3[)?#ZX955HUK")QOZ 2
MVY!7&LLSOE>KD;RL5J.&=OB[H*C'V=)RS'[U2_S?A].E&;5T8S$Q9%I'Y#6Z
M0:VUJC5[G$N6-%@ERF:(MN4<Z[D;@K'2B[)#QZ,UA78<5J8$/Q,+EH W%PYN
MM=1_'/YR['0\FO$:MAXZ$20"&Y@H_92F$FX0Y:]Y&D>B>UL=ZQ#@XV#YMW;3
M'G%G:L&D3F20D&0(/@:/PQL>S>[4S,GV #ZUEC3%"_ >>0'IKE!22TZ@%W)]
MW(>/3:G[PNE+Q%+O*%RLL&Y8ZS;CI+;'^"RS1'I6S8@:*P6C76A3!/@TMJ!%
MIV;QV*+4L&>EOQ:KZFNZ@R;@N95?R#PQZY&AYA"31AK'5_U8'6J%@'4HJZI&
MXB^SX!AD]NPCB$E1KRGH-;2SQ_@<3F/[^H91%&+JTKIQU%PI-KYAZ 2\X]XM
M=(UWT=K))?!]RP"?["!O!*.]+I_#QQ8^OO#/PK\?Z7BT<X0?#S^'/1Y^+/R\
MX>.PW[7/]C>-W\<Z;K_+9_N]YJY'A5J2+Z3XF^#W#'XY7WL#<U*X?G1>5";$
M.T<-OT\W4%A^@\PZ4%Q:@;SW?4CX]7PXAHS3)+\[-/.4_2\EFSC,(F1"B,T,
MU3@AP2@$3!;4+1C%]TP>91R4SU8&D&?I(N8UJ#3016M+$>QU^6QD-'F<_,T"
M^MO&XSL_3,?3BS_$KJ-GS!TK8=F,I"%]KA^9T:' 5W*E$O_GA^FZ6Z_I7M"%
M#4J%V)I2[KAM$NZ:]I(2,$ZW4,N(3 9G<)N3 U36GL?*#3]&IO=6Y/H8U^LM
MNS'D^I.D-V=.H"_2"Q+P[O8GI+^YRDI-E)"<B>#"Z=A)U6Q4^@<(4\"$%9_!
MT7^\NAO8C2&>QXC9</1[&L^O^-C0G30BTUJAT+'WUK)YO+HQL;Q!ZOIJE7[Y
M18?QQ\,FPC%L)AP42O'0C]\=.=W\9J:^9N](]L8<- YOM!+XK%*S[<1%?./.
MJ=J_L35CB_=>OD[?EWEA$V3.RRS90\[1YTG\/.]-5)&_K<'7!K)&LT6I,"J@
MJCM5 BJRKJIJZO!AX1[\<,[K^.M[N2$M$V$FPS&2P&-W.;#%WG.TB;_U0%CE
MQGH6! CCMP*E:4AXJ4'00B;@$?S4 @T:)/+>R&;2;ZAN/OMG=TS&H*<68=':
M $Y>T$8!<I-,6)$X'M>GV1^S#6C;UC*AXX#/K.)'TE_7W8U)?%IX;,MC)Y//
M=\S&7XZ=ACVG+P@=V_J&::&%)[7L/_<E,MPIR GT1*Y?-YO-\7/O/=V(-KLP
M%1GY/;#Y^&J=5TEEED(@ PS&-]U!D\O:0P;7)78E"1O:D'?VJL]Q\]#G\>V[
M9N)_Q/'@][]Y]VS<//193%_UJ=PCM5:AT]<8^,+O4:$/>&[%Q[CY]O%QTU#I
M/4-^]^V[Y@C]_WKL3'Q[S$Q\>\1$O.?1'0/BYV6=CNTG+^%[]T^3E/EOW3T3
M?,0SQW_(W_WV73.$O[]Y]QQ\^^ZI^.N[9N ;8V;@CV[['68N68/:6JJ0;:/@
M,:;,G'1Q48M[G7OGJ=6C!]7SQ5D]5'(!>>_Y,/39I?C&6-V73YI#,QYHNZ>8
M'> )0O(0]RBM0>ZU:.5F?.#'\V@O4%MO&!Y[M-:==16SL3D+SB>(J_:/1TY&
MXJ]R,?F5?/@/A.T>SQOB38N%Q[*AD-4;/\]?G4+;TNMU./"]X=JJ35&#&HPU
ML6E>&W_V@/&8LMKL#2<,U+;$H#]>N!TU6%LT23:=I:4G90R!9-U_S]3R.?V)
M6%@P!"57K/#2[@)J#5GW2-LLG)9-&A=2M?"9\)K)@CISO@R;#I_%UJ,EV'K$
M//@Z_'WCX^:S;4>+I:DM=S @81@WU+%<OZZ*EM$J%M^H6BY)>293J:*V%IL.
MGU&:1:*=/19.T^#K8FPY6H)M1\YCVQ$^%V/;X7/8?O L+I=6MMKEPS8.5ZIK
ML/7H.6P^4HSM1\_*N65>@]<V\QQI?)QS>]S.OWUN?-R^M\^-O\?C]AB?&W_/
M?F:/AW\__%BDX_:W]ME^W[[GLST6_OOFCA\YA^V'=3ZV'"W&#L[)D7/8>/@<
M-NX^C(J*UL]-)!Z4I"D3_Z?71(#/E$_8A XC?%2K ;#K> F6?KH!#TQ;@7]]
M-!..H>RK.5$-A&&T"$T+LF#LS\36C#48?US:QA##GGD-6OJW3]5KTXTY>#S^
M_H%9N'W<"YB]I@">/<=1)5W?@T.79A :']4-<D4FR0; E".4C['6X+7[K,.
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M_\!)V2V8A9!:K,D46KHZM9Y%.KF,GHL;ACR/#S=J=W5K=7!A"J@U$.(-"2?
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MK+V DHI#V'/V4ZP_F(;E@?N1F9^*+$\WW7=4LMAUL^U<?S>DY?\7\O=EHXX
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M&'P9?*$#)-A7G\&F8ZNQS'>?A!CRQ"M /NF+'&\RTM?=BH]W3$1MG<E$97C
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M-J-_?=//42-[#P*7J@YC<>'=DAN@WB+;LJQI<DOK@$\((>.A0X]_=&,N"_P
M3O;/%9>N*C)LU?;%WED42 W63OSSU58RC".IP=JB"9CKHD5L2WY2D.WMC2S7
M;=@L"55Z7URF^K#A#\X[UV.-^8"O[?JTK]MJK"T[SW4!?,JIZDKAY&JB@!)Q
MTDN?P]'O62EEN$$R/&=*%Q?9O<'NUR?'9\C.[8[;Y^)O'_XEIG]Q%Q9N8?Q#
M"RUMC59VH#MRF-!2LEZ8CS.DDZ 9="I,6T:\:\>((D+-XCF'%WUW(]O#SOH4
M/$QVZ"/9G5\>43<.[RD6\"DPD0')J$H/69M,.)+2AWB?5>CP?/8\EM&C U\/
M+-LP!E4U97)?)BRC<]3:?T48QII+Y;&F%E^B)+?L.K-&KLR^F";\C!TGWX*3
M?5\E-J7E,;G^'LC*[X.B,Q^:[X<RYU2IT#'$"WS*7R2A4 .7*X]BF?\N.'U:
M_\;V6+0^,UT)V'S\%;EVN)+1]OQI@4^!F-L]K=G^!-)IN8J70>-QW )G;='3
M8FYQY!)",):_N95F@8]WO7Y_GNPDPK4K90]42-;WQNXS[QLZR\E#EHLM:Q#+
M@8I0I7R/^SWFNN@%8ELQC4LRZWOS22UAXI@N51[%D@UC-6'']#AE2[6V<W7:
MM4 C5!6'HQ<\8"Q9=B.1V#'+4WK!69"*726:R=F^\QEK;81_)F3$P9(OD+V>
M'6\2Q<W/6D[)[N0N'JYD?+IS"LY*LI<QLX5--$E+%5;2@+)![+\@&+)Y?% &
M-[MFP\?5^M?7#?#1ZF)9M0A+%GC6:9%U>54UDA^?#\>@*7",U5@?^W<&&UBS
MA^=H'J<UR-W;9\,Q9!:^]TL6PMZ#%S;2UB-G   @ $E$052QNP3!H)^X --=
M"?AB3X:L/TZ)^)@%&+C4K!;2>H*VO;")/A:R8TG%7KS@O4T*JS7+SZ3CKT]%
MT1FS> RS11N;,J/1SCD+HIE1</#:5MC%\2R")Z3A4K'1:_,#CCJ2Q=<#RS>,
M0'GM*4G6J<4%U.(*6&Q;A])6/22V%7,AA0-?6#D#ZQ[=O5!D!:Q8$8R3\;\*
MO+?C>3!^FA-@G1D;0/>2FJ;EOOMQN=HV0;"*G+HI>?_Q 1]I1B'!>=%Q'CWG
M1?;ZP=(3E9X,9G-F^U,PW],7IX(%]9;6[?4<X@/.9.#H<MV9@#6C8K7T$F!>
MO8$>%6U&H!X5O1>=_\867RC&)ZY.\D@]<*IL*W(\ V0?-Z&SOQ<R"OX3[VQ7
M4"55>&XJK_H?UZ\Q*JQU >!+Z3C279H\TSWG]+-'[=U@DPO[=ZGR")86CD66
M)-38.K[(KD[UMNBU^/N6Q?A"\R&_![#KS+LFCLEZ3I.+P/K"@MM14KY'AA9M
MS7;T<2$SKN#C[<^+JYT*E[CI90<5!6RV]%O@'8P/=CZ'O<6?R"X.EKY\MB"N
MRC7YP=*$KTE/,W_!X_;SMG^^+H!/A((L</[#W<Y)) I>;2KKW7,"-X^:",>H
MZ=+.[*:1<Q3XV,QZS"S<.'HF;AC%;B_IN&&TB?L-F87_^N6OD>FY$_,VFTPI
M%MD6/H0RVZ'%N,VX>.2E9!FU/9%#$]P6YR:3&"$"R#YXN6ZF%]/W3F9D4]L>
M6.0;CK-7M+[1,ESD<9#8QL5I[I_OV4[I:OZH\ZF5&:HUM-9/).!CRZUY@3YX
M8\NO\-:6WV+-EL?E^>W-3V#-YB?PUI;?R&/-EM_ /NPQ/MMC?.9[]BK=><)J
MS='H'@GX:#6G(,N=C**SQN(3NM 5K)KLN8H]6.B[0]QP>;*]"MVC?:5-W,=[
M66C-"!1=;+RNSI7PN)Q'J=J\JY._54% .O+OX/DOX,SO+^.SS;VY+^)2_QVX
M7'E2OM.R?2JCT:.EQU6(R9C.Y</IHB6E.SD0H#BFQ>Y[<;'"]($UBH_R@PRS
MD<77$/A4-R*UJ_'F]M_"R6;6IM=NMK\[%GB&H=B4D8@U*:50UJO!L7&N5':4
MUYS%\L!]6I_'I!;&"@MNP:=[IHD"QGGA'UV=2PNMYT0M^HPVC?$I+XA2J6R'
MP)$5LKN"YA]HYCFM^96%#Z&R6O<\C+QF6SI/;?<])M?P[W+%,:SP/B@-YL6+
MQJV\I(Z3>05]D,V$KX);I;?K,O\#^'3W'.PY^Q&N5*E"*"<1V6 4%)'U*N_5
M\@NME_:\]^L(^'229'$$+2_-7B2Q9KSV!1S]G\$-(^?@QE'&PAO+^)Z"8!=:
M?M+3<Q9NN',&;F0VZ)!IN.6IGR++/PIY&Q.0E=\/A\ZIB],2E8"G0*O"/S9(
MM!TCV>M?S3/ILN7H:[*3N;J#"/#4N+MCQ8:Q9C-=$_Z*J459:\]T@:FO0W5]
MF32U=1W,0L&AO(@/]Z$\A#_X/=>A' 0.KD19#3<0);T4^*CN\5Y%[8M@\=%J
MRJ*+UI. #.^MDN67X>T!IX>[P_>0F"6W+&KI8^;Z?T7!H>8:/H<#GXWQ:5PX
MJR ).\^:;$VQ+$(+E73?>'RE=)C/#3 90K.'Q9IPI6!OR0>ROBU?B;8<M\7'
MBUH-6$Z'K:?93)NQ:DTG)_@Q&_*5S0^CJM985P*T'<.G'-6Q"X7(+=!MJ;1?
M:"\1?@O==^)LN=GD5(2;NLL-SC0"OA0X/9K<4FMB;L(W ':<7 /G>NV3*C%$
M7RHRUG>36C^:A907"J@4F.IE$. S%RHZ_8Z"B_1A9=/QGLAQ]<'1"U8.* \0
M^)8%@4_;Z+6UJU/7NJV]K<?G>[*0Z2;(\J&].=,\_X$/]HP34-8P#)=,Q\QG
MK.MHLHHJ?F?*MN"EP(/2NS6'69Z214^O&FM<M=M.=B'[Q?9$INL6./-3L<1_
M-S[:.P'[BS]&5;#7J"V#L/=H0P3M?[_7"?"IU4&A2#N#3B)UOW&QD-@U4N,W
M8L++<-PV#5WN)."I:U,!3S>N%>!C;=]HUOC-UEC@T&GH2?#+'XO <7:5X+E)
M6+5(.*'ZWM;QV4EH?^+'8K38GVFPF8)GT]%7D)[/HG5FHJG+A%EA!+Z:&LV0
M"[D:H]^3=15I3 ZHJK^"E_SW8<[Z?Y.]QC+<W2(_NQH>GY/_GWC!-1SGJ_>)
MU2.N*-$NR-04YAQU4U<G%P\S&YFTP:Q;W4F"K]4"D]BEO#9QS&9>I[EOD4U9
M%3*BSRD_;QKC4U>G+6<0D6TT4W$[<I>1^G*\L>WW2'=W,]LR,;.1?3)OQ0K_
M?2BM/BWW2O[2##Q26(&,UU2+3WNJ1L[J-"X\JRL *#B<A_2"!,SG+@8LTPDD
M2LWJVSN>H,TBUU,+,_H\Q^:K^'['^R@NWX$%_I'(\B<@NU!=A*P?I55VNF*[
MDM\ GV1BJH'5+/!I D@]*JI/89G_A]+)1<LW6.S> R\5_A@UM25D;?%.\+Y%
M@[5N=9'1E7A_^_/(+.AF2IQ2D>'I@5<W/H::NC)#+QWB10&^L<CV,!E.>:[M
M+3X=HHR3R2([9\HFQ^*VEHV8DS&WX!9\)-:HP3Z9__CFI2WGV)Z+B1>TKC7?
MGMUF3N&CW5.0E3] \@DD=T)BL=PKD%L6&1YE3:*/(,A=8;HB)[\/7BY\$!L/
M+T=YE6Y:39D0<H=WS+U>)\#'FU7WA&AOLE"HP5%H<.<%U30V'-F);]SS!!S#
MF>5)L#-N3;X>/0LWC$K'#:,RX)"-;(T%."H3CL$3D?3D,RBN,-U+3,-?2:*1
MNB1M"]62[AN6$:[=LS*)=0-O.OHRTO*Y6'MA'O?'\VG#Y^4;[T)M-;?/H= G
M+54CCCQN;6E%*4+Q3$;DUD"KMCP$[N@<&738WJL7%GAU*Q9I"N!/EHS'9?ZQ
MN%0=YF85862M28ZH*?!)*8:?^Z/UE*X0>;);,X&<FB0U?KXF4+3DD8"Y[G^#
MYX@MI(ZVF%3H10:^4 &[NF@5/(G>(F1EVYZ=6.@>(?%5W=N1X,V]Q1*P;I])
M+))=TA7TZ+JSORTZ\ZX6H<<H9^!<J=*BX\P_F(L,[A1O:E.I+&2Z$O#.#L:\
MJD2KX)4BSW$T&K3^.$<E;M_ '5+?2,"8[Z6[*TDVNCU=H8V\;=VI6KYZ+]&R
M.L7BXVV+-:?66/Z^=*2[M,#;MDESNE-PZ%R^G(SY )05^AN23'FX^,I.Y'F'
MR/QP7+2LN(_=YN.FU9SU0HBK\PB6%8X-;OK:UN4,:I4:,#/:Y<=%T\P^?G25
M$RA8O]<='QO@X_1WU%PV>YV@L< QZ1RRR\[1D@#>W?9[S',/DI(JNFIS MP&
MCCM+T(KEO5&![2O*+)7S+'INUJ=@A?\'*#I#[XA,N"@Q=-5;HZ?9,5V%)7S=
M !\7A0;:U +37A'&2J!F6;8;K^[X*?Y[Q7VXX8[?26$[+3^MY^-^?=.UK$'J
M^MC,FG&_V9#L3]G-82(&/?,"2JY4R*QI;"#$6%R<HME?!3';<Z(:G%O57+F/
M34=6(IW-BJ6/I/8D9=KWT@UC94-*?DE^:S7AB/>G-3:DOUC;G(K:<JS:_&,#
M?&3>Q@]U"2K@&=<;$P=\";*3]^7J TIG<7>J<%7.YN%(P,<&RWV0[1H$IWN@
MN*.D4-M]&W)< Y"3?UM<C[F?)<%[T&XS%5VX<S21@2]4P-X ^$0IHY*F0CEP
M9"DR\KG8M;:.=&+CX]S\VW#T@A7,JNF'9RL7G7D/&06Q+#XC8.1Z0DIX#K]@
M8D(:RZ6ED%F0@#7;G_S_V_ORX#BK:T^15&JFYDTR]?Z>J?EC9JKFCSS&V)8M
M6=[ .S;>X$$6\G@0LO"RD+PP"2%  AALL+5U2[+E#1L,#F$'&S .!JMWM2Q;
MDA=Y7R7+\J9]7WY3OW/N[?XD=;=6FTQHN=K=_?6WW'O.N6>[9P$3OP6R,?$;
M?_Y]Z&J8U_)Y5\7B6R#=#K1 A+HZU_GO0JVU^$SP&)]EP); XM-T!BH(XHT!
M4-401)Z/02[,>YPAP419/O:/>U8[C8A$5;>9X,KLQ0;/;$:FC^VY6*=W)MRA
MB=@86H2Z]@L"*Z=+E&UUI')+I%H,\_C&+JI3!9^8-K(%0&;_Z>$5JLC(VC*"
MSS\>NX^RZ[SB?S3XN3'7*C^1@@I4,.2O$Y?J*N ]F8/7]_U0UG"6=[PT0)82
MBB6,."=OFB'UDD61IK?"GP[7WNGPGW))P7>U_&Z.XO8W(_AT47!7*%IEPJH6
M-4VEV!KZ9^3XQV%CV3S<N?I'2%GP1Z0LS9229K<LR])$]GM6(N7N5=JYG:Y.
MZ=J^"K?(L4RDS'H2,Q[;@.KK+8HOT_:%]J1HX@F%PXUA'L,G3EIG&BG(2514
MOXT<#\/JN4^@N8HN"K[296AENP\Q&DA,2K"QGZ>! 3S)AEKW=+?@U?"]>+'H
M?R/3=]N 5Y9O''*\_P1W@-&0U*8I&*=+I_*70_=AN(+/'4K#YO 2G+Z^&Q?J
MPZBN"Z.JOD0^7Z@/XF)]\;!>5=>#:&BSW9SCX4X7;CS!=\14;G$*/H&?M=QZ
M@?;N!KQ5^F-M'"J1>3.E1JSTD2MY *T,4A"ECFY.'0?Q1HMOL 1VT:P=@N_P
MY?>0Z]'*,E1TB'/F@+%+?6N/R4E-B.=X<!C9<<[C?%T0;A^[CFN2.2TR5R@#
MA?ZEN-)V2-:9R#L9%P/6Y!!V'K%%JFW),KO'UR3G:&"/TCF[K;Q=_FMD^C5Y
MFGM]K)6ZP;\(]6TV:5_V2 3&O$%'3SVVESXD;E'K-J>K[:^5K&2D.G8BP3?6
M%I^L/Q'05K4$OCB>B2R_IEB(NSLT50)O/CK*/;Y$ZW5D^++T-[+W6 *)QS20
M2P8,KH=F7*@O@>]4'MXH>03YW@7(]/T?B3L@CR!]"*^09LG:YBO+<QN*3K$F
M:71/>V1C'#I<_F8$GS5OZ=MW1A2>O>[!IN!2Y/C&BQME[;YT%)0LP6V_>00I
M<[4S.UV>MRREE?<B4NY9B:^Q>:T$NZ@[]):[>8RNSRRDS'H*$W^2BX/G:A57
M$LAAB@Q+GZRA ^]&(R?V_57P"5,$<.:Z%_G^.R*]T:0C0R@5ZT+S<;%)@PMB
MW\<YSRA16\VTIZ<3!R]^@-#9S2@YOW7 BV'L!\Z]AK?+?RS,5_?F6/^0%M\_
M#UOPY892L36\#%TPO;GL2AKE>^*Y.P5?C'0&A^ 3#[ )4.$>C;KDE8M7-^R3
M!>Z2NK LKS4=>25I$OSB.9DO%JX&JFC$,J=TN/9]Y)A^A+'W^,CXE/GQ6?P[
M>ZT(N44LO&YS-C-D;VU3: GJVG6_)/%\G3@?_6>.Z>35SZ1ZB[@@96],R[IM
M"MR#^C:U^L7SR#DP14E<.TQG< H^9U1G=*]2YDW7%SNN5+^-+$\Z\L/LX:C5
M;K*\J3AP(=J=73U&<CK.7/=)2HJ4'V-N7,E$N'PS</ZZ3TZ0;6<)'E+8]K?X
M$@D^F8()/.+-AI;.H%:_=<GRNI(+6\%D]3Q&K)H:L"Y&=88?0FNG[L]3(;^9
M.(W_K*CB%CW'TB?7 \>IL+?_LVQ==5T)/"?SI,$NZ=T5T.AS%KEFBAES =DK
M-'MO!@Y=- 4C;H+R]C<C^(A@"CW6Z[3ND+*JO\#MFX?L((F=W=/3L#:8@<+]
M4_&B9SG^^\,_1\J=%':T\E[ UR6E88T(/>;S24Z?5'@Q'=S9R/;NE4B9]Q3^
MZW=78;=I9R16$=U\H^AQ%26&T3.4Q/<B@=$&T7W/JZVGL2%X)URR)V8[S*<C
MV\,\/A-=. @AV7TDWC=JW5@WAB7CV._^TVYD>F_5H!31Q"=@<_CN$0D^YE&)
ME4IMUU%/D&/2<?6%K3W>_[?^W^/#TRGX;%0G-5*3Q^<0?%8(64N$SY!]-</(
M/6<*)="%U[+]%?<XV >QP#<;9QLLL^V1)J2$Y*':=Z$=V&GQQ"Y9IL^BA:#C
MK+Y6BKRBN5I\W>3,N1D1&)B.JF8-)+EYC%+I(7CV963[Z.;5P*J"XIG("4W
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MD.EE3<9)8N&10;,VHPHTNX]G"-I6HF?$F+PH]!@F/@ENWVP<JKP),CD  "
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MO #5#3Y<;:Q$37,Y+C<=Q-6F"M0V'9+/_#Z\UV%4-U;@6OL9P4%$V(F05^;
M0<83?,-+9R#3X5RC&B^9/_]89Y(A]WDE$\2Z4RLE0]HMQ7=U)J(/6H"D,>Z5
M7,2;!Q[!&A^M?%4BB6]QEX78WVTR"D/+X#U;@*O-3-6Q]"I#B_M?1T\KSE[U
MXM.*I^#VWHY<_T19F[RW"#X1?I.16S0)_I-KQ?5FE3KE";''/QK!)P);_N.P
MN[&K\EG9:Y28 '$9ZW8)QY?M24/HG :&Q%]K!E\1BV]YQ.)35^?8=6=PKM.!
MGZ/MJJXT'\+FX'U8(Q&_M#RU* !Y86XH'9F^*7BU]$%47'P7+>T:\=D'B0X>
M[#S>W%Z-\@O;\$KH7@GX49>P*@F"4_\4K-V[ *>O[I7+U&NEBE!-?1FV'_B)
MZ;JN'3)RP[=+4")[ZYV\O!N=IN.]\YG]/W=T74?P]'KD>F8BUWC[I*U9<08R
M_>/P5OEOT$7%-P8_'PBSD?%(>Y]!!!\9N8Q#-0AQ7UCKCXR,A--WP[.EXRI*
MSK^*K>'[Q"TB 2ABN6GD66SA1Q^OFO=K@TSBM *1F^;3D!?*$!? .V4_P[56
M4_A6,*,^>CL9Y[M:G@P&4 OE\[(3^)\_8+[>,Y+83E>G"$"F,4B%%R:Z][/T
MG()OV8OX.E_2 )<ESU8@9?;OD/J+?+SR61F:.J)F/!%')J#N2(Y1@TD4F-:M
M&)LQ..<PW,^JI>DX6!OO_?)?(JLH53IB,\V!R;$,1G"+()R$'#91]<S&FP=^
M N^Y;%1>VH$+=:6XUG(*#6UGI6[>M>8CJ*H+XMBE3['_XNO8>?AIO%KR /**
MYL#EX5ZBR>%B[RVZ+(*3L3F\'/6=9X3NU?)5!L/YQ!-\5'PHG M]2[#>MP0%
MP458%UB(#?X%*/3?A<+ PN&]_ NQP7<7\KZ8CSV5K/RNR@;QHOLCI&/50L<F
MJI,JC1&F=/6(%T2.H+.W!>^4/8K,@+H\"T(SU9MA%,'8KLY!Z$.>H;AN[*K&
MVP=^A:R]O/]$*='%=5809#^TZ<@+C1>EL3!P%]ZO^'>45+^,DY?WX%+C0:EF
MTMA^7M;5^;H2'+WT/HI.K9&.#V[?+&3Y4J7F*,M^22%R":1AS\?)R"F:!M\I
M"A<-?"%^N=JL0AR+?F,+OJ&E,XAB+8!5EGKZVA?(]7%^W!8A_="*((VG89W_
M3M2U:$YNK''HL?B"+Y&K4\=!^M%Q#&6/+_X82"OJ*;,1[]7U)=@:N@_97K94
MHA6KRC_;^C!P+2<X#MG>J=A:?!_^>OQ/.'3I79ROVX>ZMK-HZ:Q%2^<5U+6?
MQX6ZL$2[[S[^/#:'OH-L[V1M,Q;QH&FYO-S@..1Y9^/8Y8_-FNU"E^IO\GW_
M^7?PTIY)<(7'JR 6_C%3"K&[ N.0YYF.]RI^A8,U[^%*RW%T=M>CN[L)/5T-
MT@S[8E,EPM6OXK72?T5NT63D22H*O7@:%.4.3L):SR*<;RA7@$I_Q=$)MH3P
M[NU% L'G?+ *./'E&C>)U>ITI$!=^VF$SF[$UM#]4JV=[5*(,"X\U2YT/R.V
MX*-+DS7;^*+0TU!MAKFR^#*;%NZI7(G.'MU?4S><W8=PCM/Y61/EA4B-E7VJ
MYCJF/58H'1I2EK)C ],8C'M3RIK%%WQJ)6IG=[F.0I*O!<\A9<Z?,.Z1?*S_
M*(3KIM^?PD5=2-2QZ1BE8-(*]>JP$28\AMH-N2V9CEU '3W7\,5QE]0\9:LB
MXH)U),EHQ8W,CN%L;</&D-Y4Y'BGH" P&X7%BU"X;QG6ERS#NN*%R _,1:[G
M=N04I2/7-T%*+%$YX7Y57@FCLE1IH5;*/;Z-@;O0T*%)J#I'6D.J1"GC&VCQ
MD2ZDJT$H#7FA5+C"9+B3D!>:) $<;C:HE<_\/O07D\(_/?J,"#X^6U#@= 5%
M++[1IC.0]@A_LT!$,-%+HB[/B\T5R/<OE+$7!&]7^$LZ0KS@ED$$'TE)_NG]
M6>KMTX//(*=HJA2)9O )F;=$2@NC8Y^\R<CU3P!=H+E>"L6Y*"Q9C,*2Y2@,
M+T2!?PYR/-.10P89F !WF+AE:LQT% 1).^F20K'&-UG2,BHNOJU^40H <7%:
M%[_"(1;S&97@DV ?52JHOG3U-HB SO4S7]+2]72Q:#XZ_'MFBPF^8XU#CW&<
M*KUN1CI#O'&0+\AOPJQ44:]K.X:W#SR*S*+)FH]KA$2!"'EUZ5)@Y'BY=Y^!
M_, LK"]9A(W[[\;&??^,C>'%*/#-%?=AKC<5KF JR$_=X9GB:5C'?<3P%*QA
MO$3@+AR[_*FP+'4FL_FWK=1!Y:T=P=.;A0_GALA'Z+)GKC"5:?+L*:  S/5,
MQH;0(KQ:^CULVW\_MI7>C]?VW2NTDN,AGZ'7C[R"KG+-P<X)LS-#.O9':LU2
MH8@:5_%@-MKC@P@^HQV3@&3#4A>C%79TF]0TE6//\1QL#"Z7S>8<<6E.06&0
M[>>Y[S #KA(*,C-AH^7V%8!&\ E0>.XTN$O299$6^.8A?($ATJ;,#_F*)('J
MGE$B $0W@+DP53NN;^_ PWD[D#+[:>GD+B7.3&"+!KC$$WYL@41AQV[O[/]G
M+,7E*W'+LI5(N?-/2)G])/[7@]EX>LLNG+@0#8(1%M7;A6[9_Q0)"/0R)6*L
M$4S@\)X4-%$L':G]&!O#W\%J+H 0%1(C9(R&S.[(%#I"E,R+#*7"'9PLY9O(
M+%F&BOYX_JX"4RUTNDU=)5-%>+(>(OLETJ7W[O['T-99)?M$4I;.AG%S3#*N
M&()/<MW(K)46[%Y-A'&+H-6],3*YH;QXCTP_.UJSL:<*)-)+5.%P6GP#NS,,
MS]5IF9?%KV&ZLF[T.<7GM\!5I-VI97Z2YA _CR\>;9,54<2(^D2:,LX&"MGR
M"W_!AL 2K/%/0':8">8L!,S(2\T-XWKD_A'QR>T'=_$$:=":%V)]4=(&7;!T
ML6F ![^S@# %8&YP/'*_2,=[!QY%34.)U>V,#JQ;(9H+IDI>K/''%GQ#2V>0
M]!U17@AKG73QF5>1543:M-ZAZ7![,W BLE>DPBW66%11B2WXN$;&/IW!T(@5
M=.9=HSOI(E"7IU5<V[OKX#NS#OG^N5CMOPVY4BR A@3['UI\<MUR/:>+4L7U
MS;6;SXHH(>)>A0S/H?M;8R78-S,=V443\>;^7^"2*76GE3ET]TIL=Z;/</M&
MEFT/RBZ^#S88SO%HK(9$GAKKCT*0"C"54K8F<P5HF:8AJS@5N6%=6T);8L&J
M$90;G"AN3_^9C<+357$G7X\-I]@X'-FY@P@^U5B%R)0^9(^@N?,4#EYZ#^^6
M_Q;Y_IE8X[T5V<$)VB% -/,IR MJ'HV+16)#3#0G4-+,.S_'>!6GPB7U'C.0
MXYV ;:$?X)SIGR6:.GF7N%9))"3H^*Y.)6KN06I$7#<%0K=JQURQ^3N+\8_+
MGD/*W#\B9<F+2%G,](55FL"^)-8[SS'G\?>E*Y&RE GO+^EQ^;X**0M>0,J,
MI_"MI<_BGN=>P5\"AW"M/1H(0Q8HI,1]/[,G-%8(M7N*UO+3_4;E3VSKXCE=
M@$V!NY%=E"JMGG1OSJ2-&"V,3))!*F(=2G@XB93,F4*/UC@9IRXTYAGE!,9+
MT,-:[WR\5_8H*B]](*V%1)'F% EW$^%'AFT%W^YC*[#&R[U?6G*&-HJIW;*1
M*6L^9HC =5.;9,N;4/H(7I.0Z9F 3RM?,(*/XR'8K46B JFL^L_(]$Z$JYAN
M&-+H9+%^V?B5?^*PC##<> O-WM/^K@J(&H#<#@ Z>NOQYH%_0S:C/".6+(LH
M<WZ3\9+W5F%T?*:,,P$#$*''M2!K0BUJA2U0UW9&FIPR63[3>QNDPPE=TJ:\
M&7&HWA4*-]WGH8+!M 1A3A)*3T65ZS9#RI!E>U/%Q5U1_19Z>AL4+@0?/0P2
M96QVKP5.@PN^'8=_BS6^;PON"?=L_P2\4?HS)*K<HH%C=@N!$P?J6D]B;6"A
M=JP(ILE8M^V['VULPBQP3*1<JE#D>;3X-H672,0Y:8[TML;_3WBWXI?"]H7Y
M1_"A\Q8:!_!)Y5/(](Z+\#?FIKG\4W"Q03N_#+:^J3F(N],JB()3&;[\QX;,
M.PX_ ;=OCNRKL6J-]"4T57,*B$_!J>)/+'U1!"CHB,<I$NDJRDL@55RHA?[%
M")[9)&Y)@9,HY?3**$Q$>::!(?A56/.\2TT'L:/\=W!Y,I#EO]58HWRNH1U1
MD/F903/D'7PICZ$"10')FIRD2\9KG+BBEB9QJ95=^J\CNY[&]CV!X.-DK8 !
M.KI:<.%**?Q'"K ]^#!<17-DT[L@.!OK0G.Q+C@/ZX+SS?L\% 3OQ-K0 OT>
M6(#"0/0W/9?G1U\%H7E8&[Q3CA5ZY^.3PT\+,0KFF<<D/F=.WA"RJ.V)B)KG
M$HBZ"&W@ :=D_TJ.5V':+_+Q'Q<]AV\N78G_LO0Y?&OI\_CF,O/BY\CW%_ M
M.>=Y?&OI"OS#LN?Q#\M?D.N^M837OB OWH>_?6/Q,TB9\P3^P[S'D?'CU7AA
MPX<H.WH6;9TL_*0YHVI%CQU"J2E9:\:ZGKCHY(%&<:EK.X[B\YNPO?01Y/OF
M(-LW#KFTU'P3X JJ6XNAX-PGD1?+GXDRDH;LP"1D^5-EDYOM83;Y[\1;)3]'
MZ,P65#>41;H#<'KJUK5S4SPH R"_:L>>H]G(VSL'A:$[L#8T6X)DU@47B/N-
MWTDOA0'2SWRL#2F=% ;FP?ERTL^ XX%YV!"8@X+/YV'/$9<XFX51$?@2@*0+
MC&,MK_H ^45W8%UPKCQK?6 ."O<N0&7MAT(J<IT(&3N?6.]VP1J!)TR2QV1%
M*PX G*LOQD;_(A0&YJ(PN$CG&U@L=.\JRD#H#%,0!A=\2MMT]Q.>T7UD'K=_
MUYL.2]CZMI('X?;.D&C!;/]XZ>Y G.J^:CI<X31],0F=I=4"$Y'M3Y4 $>)@
MQ_['<:3F';0ZH@DY+UHFBE-50$E[JB3$@H\>L\+YDT//P>V9)C!?%UR( M\L
MO+/_W]$-VX%]X#U(QT+CXJHV]T,;=A]9!9=G%M8'9J.@:":"9U\Q,.0%=HRQ
M[B?,0<ZMZSB+;<7W8ZV?M#@?A:%YR/-.PX<5O],AR_K1$ET:[M@6<9/^]?!J
MY'NF"Q]<&R*?FX-"WQQ4-]C26S)P ZO8XR OH(HH\#1> LOK%)_=J+X>P&?'
M5F%+Z#MP>[A'?QL8Y4[+B@J*XI2I'%S'4P2G5'K8[#;+EX9LWS1L#?T+_"?6
MXFJKCHWWYK,5KNI%4 6:L%;^*C"4*:@;EB,]?G6/I.IL]"Z2:'UY1E -%S>]
M!.+MH]!-ARN0(;TG<WVW(=<[!9O"]\-WKK /?^=<(SPZHF ,A)72V^B/)Q1\
M"G@EG):.1E1=.X(SUX*XT%",FJ8#J&DJ$U<GW9WZV7[G^PA>C8=1TW@ EYO*
MT0/3FD*(8/03=0*,0M3ZAQK:.A \>@'!XS78=ZP*X6-5*#ZN+WYV?N=Q/58=
MYWC_\ZL1.%:-O0?/8D_X*$H/GT9S:XM:JJ+EC>V\G'.,]=DR'1([K8_S]6&4
M5KV!G0=7X*V*7V-#\=UP^V<B+S 5>8%IR _,@#N0@3S?#+Q<O!SOEO\".\O^
M"/_)=:B\_"$N-5=(X(8N3/ZOC)Z\/M;SY9C,NPOUK56XU' 0-4W[<;'I "XV
M53AHQDE/(Z C0WL7&P_@8D,YKK=>0(^XE@EO'9LN9G4:MG1<06U#J>2:DJZK
M2<^-Y6CNJC7GDP%HV;"X\TJX6/E,/DO$ JZU5N)B8QEJFO?+_&L:#^E[0PD:
MVJL-["A,+#R'1R>B=!A%AUAAK\ SUP((G-V"#RN>Q)L'?HH-@3N1[Y\.=X#%
M@6<@SS\-!?[;I;C$N^6/XJ^'7\"AF@]PN?DP@&B*21]!FPC/">!!.JQO.8M+
M#:6H:0ZCIND@+C66X7K+49-3&H]^>-PJ%@:/Z$!+1Q4N-NY'36,9:AL.H*.K
M26$G+:WBW<O2@H@;,(KU<A/Y3YFAQS)4-Y;A:LLQHW3KL\F<Z;[O0:>XFBDD
MZEK/"]\2NFDJE[F0GCJZM.FM^H*'A\,HG?&Y5&:,/UNLTVH<O_*9=#;_L.QQ
M;-__  K\L^'V3Y-UZPH0K].1YYN%UTJ_CP_+?@OOL74X<74/FKL8;:WWLFO!
M"MCH]UACM7 434N6/!6NR\U'45']'CZM6(FWRQ[!AL!\Y/NG(L_/2BPSD.>;
MCLW%=TMPUQ='LW"\=C>:.VHB+",ZSUC/O'''$@@^M1ZHQ9G5'QGLS?H0K_K#
M:(&E/=YZT..H5W>SYL0PEYZ>=C"A=K3S&,[U9(8D=UE$QGJ)SIF+N%$B_"XU
M'D9M$U^5N-Q8*:D$/-;0?A8]J!=7=_0ZWM#H$+(70&M6=Y\2CBUJE/2YU8W\
M(KQ#M'_K > [1774_1WS^4;KE7,3,/-$\R7LY7>)?B3 %&ZQGZ<XTJ("PZ<1
M0I^)T?S'9U+ RRORL YTH@[7FD_@<@37A^7SE8:C:.JXB%ZPHWDT[8&PT[U:
MSL.ZKCDVRPR'RZ#B$(#<;[![6NM6'5(J%!Q27N;)\71"\JD3*,[$J<Y'7=$1
M$/7[H+C0O#:N%"T 9\<99RZ\AS$H1T<[2J]"/Z3?J/PSH^Q$>\]E7&DZALN-
M!W&EL0*7&P^AMND(+C<=0TL7A4Q;=$8"*N,ID/5 / ZF9/%$V\)(W#ER#=6X
MZ!]5@'I<;SZ!*PV'A)ZH2%QN.(K&MBI#4]&S.9%$:^9&_S:(X%,3V&HL?*<O
M>J2::/S)Z+Y7-SK,DN5:I7]Y-%IVHL78CJY>E@PB47%5RV:43)-CU'E&J59<
MDL9"ZPL+PD-?L8[+?2C@Q']N"$82W$V+EQ$SCD1SB_U;Q-ZP3%C&8?!+^DVP
M?BVY*J-3?5&8AJQH=>.(!25\5H5?/%P3WLJ6R4)XKEUTHV&DL>=,SDS81W'#
M9W"!:FU3LG 5U-J;L%M$!L_1O3/UY6D?-)EJQ**-_;QX<Q;F*@R8S)(6@](=
MA0F]#QR'QD-V1JR+T;I]=)M"(_-T7'R"*K,6GW'?(W3)N1.&LJ5NUOU8K'^3
M\TA^*B]^U\".^#"T,.?S23,Z+KG>I ZQ6HS2.>'(R$3>UYQKZ;[/NY/Y\ESB
M1=>$CJ/#Y'\:>K "@FM%@*)KW^[/\1I&0Y*.K *HWRDJ$XW#SFW@NU$C5<D0
M7! G=ERDI[A8C/Q@6)K0F2AA(O"LX-:UH/.UQP:.0XG6L9;X7%'>1<52I3KR
MQ($?S.D&=W;-#WR.CN/&'T\H^'00NBP5<89@#?%8AF(':[_;=WN<[[&.17\W
M/]/';9$B&PAC'P#"9T89C25V13C'J$*="V*L7B;M0E>5+%CS<10:\V@(([)F
M#4IX+XL>G;\52';QBL]?BR3UT=*XJ(4N[*(6)C;<L:F@L?1E:<+2B^(D>L^A
M'M?KC)#K@TN=HS(N:OI\&08O"YDT89D?*86+E+1@QMF'<4;'9<<=Z]V.V=Y#
MA:@^@PH\1\GK>%ROYYB&*@ABCT$T=&'4RCJ)2SY?QZ+SUO'H]2IX-1",]""_
MR5K4L6DA=,*"O]EQCHR91^:H@%"EBS"6("B.,_:<(N,2?#CQ8G&C8U6<4E@)
M0<:]GYPG:UZ9OPY'@W7DLY,.Y.'FGK)'S.?S.BKHIFZOW:.3\1/&^GQK+<6?
M5[SY4C'C<S@OPEQA).N3WVV0EFA2%D]$L5ZGZ]9)5_8<OO/EA*'%:?RQZ!CZ
MG2?PBUX373NZCJA\J!+B $<?&HI>.Q+XC/2:000?)VD R7=-_8UNA!K"B#!&
M^]V^RY(VO\8ZYF"FEE&I%D&@Z8+E_R.=7+SK2-3*^!3Q.D)^)K,AT2A_L(C6
M1=#WF,)%C_%W>Z[SN'PFS,S<HXR&<TJTP&\$,43'J,$=;*7-E\)7%PNAK8LY
M.E8E= 6*L0Q%\[26"N&E__0:,H<$<Q/KUS)@2U\&'0+[?O3B/,;G&%CJ>.V3
M8QPWYY%51/ GC(E43&>@90CZ;#U)HZAXO@HDYSDCQPG'2KI2(J'+B#"R[^IV
M4HN9SU-XCI3N9>QFK2K]&YS)>E*;5O^W5HG2<!1(<K$N#V.-6@:O^+5TQ#DE
MP'-<X:6P4#JSPITX,-93PNN4%G4<UE+A&(Q)*@) \6G7H2AG<>YIK6JK_*A5
MPP 671="Q\+8+9W1NB&MV>]<.SIV993</B/\E+ZM$B]6O:!_)#2D\[/D8WDP
MO55\D8YE3+)N]5Q=(Y9O&GP)4U/&IGB+O<[C\DSQCACZC,#3PIYS-O,VRJ.5
M^<(W9#%%Z<6..=ZS;L;Q003?0$1%D"J3=RX"GFN_VW?G];&.V6OL>;3PR!3X
MG8@CD?$ZL5(Y)P   Q%)1$%4^_M8O5NBZ'\_?2:?1]*VSXV2>?28/<?^9L]U
M'H\>B]Z7,+)$$OV]_SC&_CN1(_ 4AF\6KVB0NFR4.:MUJD#7,>M8^S,E)QPL
M7KD(^+)6>^PY<.$J;G6Q* R<\+'7V?OVQ_]0CU.Y$:X4P6,4WK1_+!,SSR/-
MB55D%[%]KG-.SGG;<0[^KC2B3$.L&M'4:67:>1M%0."GSQ@=W:MP[XL/?98R
M125!7:\<G5HM2@,&CW2%FW\*-PMWWL? 9%1KT\Q3Z%'IB[06Q5&LSWI-E,\X
MO]MQ*=XX%U%N#$YCW9=0LB^E23-WR[R=5K?<QUC$'*?@CN?;YUI\<MQV7*J0
M*:7%FL_@QZ)T8.]IZ5*_Z_JTPI[SX7KFN"R^=#PJY)WW<'[FN?QNCPT<E^4)
MY/]1>AAXGH6STAEQH :3*#81/J[\QY[[9;P/0?!9@-@)QY_LV$_@1CW3SJG_
M7)Q$9<\9[7O_9WR9WRT\C>P=P+CL8K%PB#U699"Q?K/WC_5;O&-.^,8[9S3'
M+7-RWH//M,?MF./-V?[.ZWF-\SXC^<S[]8>S\QF\9__OPWT.QVGGU_=:96!]
MCT7GQ><Z7_W/XW?[>ZS?AGHL"NOXM!3K7D.!2_3>BJNA7&.?U1\O]CC?^\_;
M>5_[FSWF' ./C99N[/T3C<?Y6__/1M%U*//#I^-88[!PZ?^\Z''%KX6+\SPG
MC)S';\[G(0B^FS.0X2,B.:XDS)(TD*2!) TD:6#X-) 4?*/6X(</]"2A)F&6
MI($D#21IX,NC@:3@2PJ^,7#??7D$G&0>2=@G:2!) \.E@:3@2PJ^I.!+TD"2
M!I(T\)6B@:3@2Q+\5XK@AZL9)L]/6A-)&OC[HX&DX$L*OJ3@2]) D@:2-/"5
MHH&DX$L2_%>*X)/:^]^?]I[$:1*GPZ6!I.!+"KZDX$O20)(&DC3PE:*!I.!+
M$OQ7BN"'JQDFST]:$TD:^/NC@:3@2PJ^I.!+TD"2!I(T\)6B@:3@2Q+\5XK@
MD]K[WY_VGL1I$J?#I8&DX$L*OJ3@2]) D@:2-/"5HH'_![ ;18ID6E_6
) $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>neologo1a.jpg
<TEXT>
begin 644 neologo1a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "T 8L# 2(  A$! Q$!_\0
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M'K",_P!_J.>N>Y%?I"E?DV.PDL'6=.6Q^O8#&1QE%5%N.HHHK@/2"FM3J:U
MGL?B)^T-_P E[^)'_8QZA_Z4/7G_ *UZ!^T-_P E\^)'_8QZA_Z4/7G_ &-?
ML>'_ -VA_A1^*8C_ 'B7J_S/W2^$_P#R2WP=_P!@>T_]$K53XV?\D<\<_P#8
M"OO_ $G>K?PG_P"26^#O^P/:?^B5JI\;/^2.>.?^P%??^D[U^2+^-\S]@?\
MNWR_0_#=:LZ?IUWJUXEK96LU[<ODK#;QL[G ).% SP ?RJLM?1'[ :AOVIO"
MH(X\J]_])9:_6Z]9T,-*JE>R/R"C15?$1I-VN['BW_"O?%7_ $+.L?\ @!+_
M /$TO_"N_%7_ $+6L?\ @!-_\37[ME!Z#\J J^@KXW_62I_S[7WGVG^K,/\
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M@H6/S'.HN.-G?J?HK_P2SUR6Y\'^.M'8 0V=[;7*$?WI4=6_(0K7W17YF?\
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MG7OZUY'"=%T\N4G]IMF&$CRTTQU(W2EI#7V9V'R3_P %-/\ DW[3?^P_;_\
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M$T\86YU21?NY'S)&/X5S^)[U[IM-?#9MFGUR7LZ?P+\3[W)\J^IQ]I47O/\
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M.<<'MVKZ6?$U:A&\^5(^8EP[A=6Y,_(C_AC/XS_]"+??]_(O_BZ/^&,_C/\
M]"+??]_(O_BZ_5G_ (77X1\S9_:>!_>\E\?^@UT&@^,-&\2IG3=0@NCW13AQ
M_P !/./PKFI\8>V?+3G%LA</81Z*3/R&_P"&,OC/_P!")??]_(O_ (NC_AC+
MXS_]")??]_(O_BZ_9+C/3]*IZMK%GH=D]Y?3I;6R8#2/T&3@?J:[)<28B$7*
M25BO]7,,M7)GX\_\,9?&?_H1+[_OY%_\72?\,9_&;_H1;[_OY%_\77ZYZ3X\
MT#6[U+2QU*"XN7!*QIG)P,GM6_44^)ZM:/-3Y6)<.X9ZJ3/R \,_LJ_';PAK
M]AK6D^#=1M-1L9EG@F26+*LIS_?Z'O[9K]2?A#XI\1>+O ]E>>+/#MQX9U]!
MY5W9SE65G &70@GY&SGGGJ.<<]QQZ5@ZUXRT;P[=);ZE?Q6LS+YBH^<E22,_
MF#7EYCFOUA*>(LK=3UL%E\,ONX3=F;PYKE?'WPS\,_$[17TOQ/H]KJUHW19T
MRR'LRMU!S6QHOB#3_$5JUSIUTEU K["Z= P ./R(_.JFJ^--%T74%LKV_BM[
MI@"(G)SR<#MZUY2Q,*<554[+N>K.,)QM+5'PM\6_^"9$ZW,][\/-;3R2,KI>
MJDY!)QA9<=,?W@:^5?&7[-/Q.\!SK'JO@S5 LCLD<EK ;A7VXR04S@<CJ!7[
M7!MR@CD=:0X[_K7U&'S[$T5:?O(^;Q'#^&K-RA[I^!-Q#):3O#/&\4T9VM'(
MI5E([$'N*CR*_</Q#K'@/0[DKJ:Z4MPS'<OV=9'W#!.X!21P1UKGH_%?PK:X
M,GV738Y <[SI_7_QRM9<:82G+EG9/U/(EPXD[>U/QCL[2?4+F.VM8);FXD;:
MD,*%G8GH  .3]!FO3O!'[+_Q1^($RKI?@[48XO-$3W%]$;9(R<'+;\': >P-
M?L-HECX7U&-;S2[73)=N"LMO"F5.,]0.#70*NT=*WEQ-*K&]&*UZWN=-+AJG
M>\YW1\"_!_\ X)DQQR17OQ%UKSQM!.E:2Q49(8$-+UXRA&W'0CO7VWX+\ >'
MOAWI":7X;T>TT:Q7)$5K&%!R2<D]3RQ[]Z->\>Z#X8D6/4M3A@E/'E<LPZ=0
M!D#GOZUCP_&KPC,VTZH$.< M$X!_3^=?(8S/(5ZG)7K*_:Y]'AL'AL'I36IW
M*K@^U.JO97UOJ$"SVTT=Q XRLD3!E/T(ZU8I1DI*\=4>F%%%%4 4444 -KS?
M]H3X1VWQM^$^N>%YEB%W-%YUA/+@"&Z0$QMG:Q49RI*C.UF KTDBCU-73G*G
M-3B]49U*<:L'3ELS\%?^)KX+\28_TK1]<TJZ[AX9[:>-O3 965E[\@BOU\_9
M<_:%L?CG\)X-9N9$M];TU!;:O"SJ6$JH#YP50,)( 6&0.0RC.W-?)W_!13]G
M%O#^NCXG>'K'_B6:@WEZW%;P@+;W!("SG!Z2DX)('S@$DF2OE#X7?$S4_A;X
MD_M+3Y)/(FC-O>6R2%!<0L02C$'IT//&0*^XQU/^ULO]O05ZD5MY]C\ZP]:I
MDN+E2G\#_JY^C/Q.\<-XX\1//&W^@09CM@5VG;GECSW/Y<<5Z#^SSX0+?:/$
M$Z\',%OS[_,>#^'([5XA\))K;XQR:<VASB6WN#F0YP80,;PP[,![=<5]J:+I
M,&@Z7;6%JNRWMT$:+G/ 'K7\YY+EN)Q.85,9CHV<7^/_  #[+"KV\O;;HO[:
M6DW49YQ7ZB>N+2-TI:0T 9?B+7K7PSH]SJ5Z6%O;KN;8,D]@ /4DC\Z^<Y9O
M$7QQ\42)#^YM(>BECY-LASC/JS8],G'8#CM_VDM2DBT[2;!67RY97E=<<Y4
M+C_OIJZ7X(^&X]%\$6UPT6RZOS]HD8X)*G[@SZ;<'!Z;C7PN-=3-,R^H<UJ<
M5>7F<4[U*GL^B*6C?L^^&[.#%Z;C4I2H#-)*44'OM"D<$^I/2J7B3]G?2;R)
MWTBYFT^?'RQR,9(_QS\V3ZYX]*];:188R[L H&2Q.,5SQ^(WA?'_ "']/_\
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MH6_C_P#\B#)_U\1_SJ3X"\?#NV!/_+:7_P!#-1_'_P#Y$&0_]/$?\ZD^ _\
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MY%.K[S#4(8:DJ5+9';&*BK+8****Z2@HI#3=_K0'F/XJ&:X2&,O(X1 ,EF(
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MZ,'-0O;R.J,:/*MC2\)^$[/P;I*Z=8&4P!V?,S!FR3D\XKQ#]I#_ )&S3_\
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
